MK-8353

Term ID

CHEBI:167664

Synonyms

(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)-N-{3-[6-(propan-2-yloxy)pyridin-3-yl]-1H-indazol-5-yl}pyrrolidine-3-carboxamide
MK 8353
MK8353
SCH-900353
SCH900353

Definition

A member of the class of indazoles that is 1H-indazole substituted by a 6-(propan-2-yloxy)pyridin-3-yl group at position 3 and by a {[(3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)pyrrolidin-3-yl]carbonyl}amino group at position 5. It is a potent and selective inhibitor of ERK1 and ERK2 in vitro (IC50 values of 23.0 nM and 8.8 nM, respectively). The drug is being developed by Merck Sharp & Dohme and is currently in clinical development for the treatment of advanced/metastatic solid tumors.

References

Ontology

ChEBI ( EBI )

Relationships

is a type of: aromatic ether dihydropyridine indazoles methyl sulfide N-alkylpyrrolidine ... Show All 10 Terms

aromatic ether dihydropyridine indazoles methyl sulfide N-alkylpyrrolidine pyridines pyrrolidinecarboxamide secondary carboxamide tertiary carboxamide triazoles Show first 5 Terms
has_role: antineoplastic agent apoptosis inducer EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor

antineoplastic agent apoptosis inducer EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor Show first 5 Terms

Phenotype

Phenotype resulting from MK-8353

Phenotype where environments contain MK-8353

Phenotype modified by environments containing MK-8353

Human Disease Model